[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lenacapavir\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lenacapavir":63},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100632840","protecting-against-lenacapavir-misinformation-with-young-women-in-gauteng-south-africa--protect-l-100632840",false,"NCT07518914","Protecting Against Lenacapavir Misinformation With Young Women in Gauteng, South Africa ( PROTECT-L)","Protecting Against Lenacapavir Misinformation With Young Women in Gauteng, South Africa","PROTECT-L","Inclusion Criteria:\n\n* Female (cisgender or transgender)\n* Age 18-29 years\n* Self-reported history of sexual activity in the past 12 months\n* Self-reported HIV-negative status or unknown HIV status at enrolment\n* Willing and able to provide consent\n* Able to read and understand English\n\nExclusion Criteria:\n\nUnwilling or unable to provide consent for study participation.",true,"FEMALE","18 Years","29 Years",{"count":22,"type":23},1500,"ESTIMATED","INTERVENTIONAL",[26],"NA","Adolescent girls and young women (AGYW) in South Africa remain disproportionately affected by HIV, with prevalence among 15-24-year-olds at 9.4% in 2024 despite expanded access to condoms, HIV testing, and oral PrEP. While oral PrEP is effective, its reliance on daily adherence and regular follow-up has limited impact for many young women. Lenacapavir (LEN), the first long-acting injectable PrEP administered twice yearly, offers a promising alternative that could improve persistence and protection. However, LEN's potential may be undermined by misinformation, particularly around safety and trust, which has been shown in other HIV prevention contexts to reduce uptake and demand. Proactive strategies, such as psychological inoculation, are therefore needed to prebunk misinformation and support future LEN implementation among AGYW.\n\nPrimary objective: To compare changes in intentions to receive Lenacapavir following misinformation exposure in groups with and without psychological inoculation and behavioural economics boost.\n\nSecondary objectives: (1) To compare believability and persuasiveness of misinformation claims and motivational threat associated with misinformation in groups with and without psychological inoculation and behavioural economics boost. (2) To explore subgroup effects by relevant sociodemographic and behavioural factors including HIV risk, PrEP history, COVID-19 vaccine history, general vaccine hesitancy, and information avoidance. The investigators will conduct a two-arm randomized controlled trial of 2-3 inoculation messages that address emerging myths and misinformation about Lenacapavir in South Africa. Participants will be randomly assigned to a control group or an intervention arm: enhanced inoculation message with insights from behavioural economics.",[29,30],"Misinformation","Lenacapavir",[32,30,33,34],"South Africa","Adolescent Girls and Young WOmen","PrEP","RECRUITING","2026-06-24",{"date":38,"type":39},"2026-06-26","ACTUAL",{"date":41,"type":39},"2026-05-19",{"date":43,"type":23},"2029-04",{"name":45,"class":46},"University of Pennsylvania","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":55,"minAge":19,"maxAge":4,"enrollmentInfo":56,"targetDuration":58,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100623854","cabotegravirlenacapavir-dual-long-acting-therapy-cohort-imea-074-100623854","NCT07402044","CABOTEGRAVIR\u002FLENACAPAVIR DUAL LONG ACTING THERAPY (COHORT IMEA 074)","CAbotégravir LENacapavir DUal Long Acting). Immuno-virological Monitoring and Safety Assessment of HIV-1 Infected Patients Receiving a Long-Acting Antiretroviral Combination of Cabotegravir and Lenacapavir","* Age ≥18 years\n* HIV-1 infection\n* Patients who started taking cabotegravir combined with lenacapavir between July 2024 and the one-year follow-up, or who are due to start taking the CAB\u002FLEN combination.\n* Patients who are due to start the CAB\u002FLEN combination following a medical decision.\n\nExclusion Criteria:\n\n* Participants' objection to the use of follow-up data","ALL",{"count":57,"type":23},50,"48 Weeks","OBSERVATIONAL","The main objective of this national study is to evaluate the virological success of long-acting antiretroviral therapy combining cabotegravir and lenacapavir. The study involves patients who have been receiving this treatment for one year or those for whom the physician decides to initiate it. It also aims to evaluate the tolerability of the treatment and changes in the participants' immunovirological profile during follow-up.",[62,63],"CABOTEGRAVIR","LENACAPAVIR",[30,65,66,67],"Cabotegravir","HIV","Multicentre cohort","NOT_YET_RECRUITING","2026-03-23",{"date":71,"type":39},"2026-03-27",{"date":73,"type":23},"2026-03-15",{"date":75,"type":23},"2028-03-15",{"name":77,"class":46},"Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba",13]